Reversal of Dose-Limiting Carboplatin-Induced Peripheral Neuropathy with TRPM8 Activator, Menthol, Enables Further Effective Chemotherapy Delivery

Dawn J. Storey, Lesley A. Colvin, Melanie J. Mackean, Rory Mitchell, Susan M. Fleetwood-Walker, Marie T. Fallon

Research output: Contribution to journalLetter

23 Citations (Scopus)

Abstract

Chemotherapy-induced peripheral neuropathy can be a major dose-limiting side effect and leave some cancer patients with long-term pain and functional disability. In some cases, the neuropathy can be so severe as to preclude further life-prolonging chemotherapy. It is important to find interventions to reduce such effects while enabling effective chemotherapy dose delivery, improved survival, and good quality of life.
Original languageEnglish
Pages (from-to)e2-e4
Number of pages3
JournalJournal of Pain and Symptom Management
Volume39
Issue number6
Early online date8 Jun 2010
DOIs
Publication statusPublished - Jun 2010

Fingerprint Dive into the research topics of 'Reversal of Dose-Limiting Carboplatin-Induced Peripheral Neuropathy with TRPM8 Activator, Menthol, Enables Further Effective Chemotherapy Delivery'. Together they form a unique fingerprint.

  • Cite this